Abstract
Unexpected effects could also occur after the marketing of clopidogrel. So, it is necessary to ensure clopidogrel continued safety once it reaches the general population. The present study aimed to describe the adverse effects reports of clopidogrel during the previous years. It included a descriptive analysis of all reported AEs associated with clopidogrel using the FDA Adverse Event Reporting System. From 1998 to the end of 2021, a total of 21566 reports of clopidogrel adverse events were submitted to FAERS. Most of the reports were submitted by healthcare professionals (88.43%). The most reported clopidogrel adverse reactions were anemia (7.88%), drug interactions (7.48%), gastrointestinal hemorrhage (6.27%), and dyspnea (5.06%). Nowadays, clopidogrel is widely used in clinical practice, so the occurrence of different side effects particularly the hematological side effects should be considered by healthcare providers. Moreover, the pharmacists should check for the interactions between clopidogrel and other medications before dispensing clopidogrel.